Karo Bio officially names Per Bengtsson CEO
This article was originally published in Scrip
Executive Summary
Karo Bio, a pharma company with development projects in indication areas including cardiovascular and metabolic disease, neuropsychiatry and inflammation, has appointed Per Bengtsson CEO. Mr Bengtsson has been acting CEO since May when Fredrik Lindgren left the company (scripintelligence.com, 27 May 2011). He was previously CEO of Probi.